The National Centre for Stereotactic Radiosurgery, Royal Hallamshire Hospital, Sheffield, UK.
Acta Neurochir (Wien). 2012 Apr;154(4):605-10. doi: 10.1007/s00701-011-1252-6. Epub 2012 Jan 10.
We present our experience in treating ocular melanoma at the National Centre for Stereotactic Radiosurgery in Sheffield, UK over the last 20 years.
We analysed 170 patients treated with Gamma Knife radiosurgery, recorded the evolution of visual acuity and complication rates, and compared their survival with 620 patients treated with eye enucleation. Different peripheral doses (using the 50% therapeutic isodose) were employed: 50-70 Gy for 24 patients, 45 Gy for 71 patients, 35 Gy for 62 patients.
There was no significant difference in survival between the 35-Gy, 45-Gy and 50- to 70-Gy groups when compared between themselves (p = 0.168) and with the enucleation group (p = 0.454). The 5-year survival rates were: 64% for 35 Gy, 62.71% for 45 Gy, 63.6% for 50-70 Gy and 65.2% for enucleated patients. Clinical variables influencing survival for radiosurgery patients were tumour volume (p = 0.014) and location (median 66.4 vs 37.36 months for juxtapapillary vs peripheral tumours, respectively; p = 0.001), while age and gender did not prove significant. Regarding complications, using 35 Gy led to more than a 50% decrease, when compared with the 45-Gy dose, in the incidence of cataract, glaucoma and retinal detachment. Retinopathy, optic neuropathy and vitreous haemorrhage were not significantly influenced. Blindness decreased dramatically from 83.7% for 45 Gy to 31.4% for 35 Gy (p = 0.006), as well as post-radiosurgery enucleation: 23.9% for 45 Gy vs 6.45% for 35 Gy (p = 0.018). Visual acuity, recorded up to 5 years post-radiosurgery, was significantly better preserved for 35 Gy than for 45 Gy (p = 0.0003).
Using 35 Gy led to a dramatic decrease in complications, vision loss and salvage enucleation, while not compromising patient survival.
我们在英国谢菲尔德国家立体定向放射外科中心展示了过去 20 年来治疗眼部黑色素瘤的经验。
我们分析了 170 例接受伽玛刀放射外科治疗的患者,记录了视力变化和并发症发生率,并将他们的生存率与 620 例接受眼球切除术治疗的患者进行了比较。采用不同的外周剂量(使用 50%治疗等剂量):24 例患者给予 50-70Gy,71 例患者给予 45Gy,62 例患者给予 35Gy。
与眼球切除术组(p=0.454)相比,当将 35Gy、45Gy 和 50-70Gy 组之间进行比较时,各组之间的生存率无显著差异(p=0.168)。5 年生存率分别为:35Gy 组 64%,45Gy 组 62.71%,50-70Gy 组 63.6%,眼球切除术组 65.2%。影响放射外科患者生存率的临床变量是肿瘤体积(p=0.014)和位置(分别为视盘旁肿瘤和周边肿瘤的中位生存时间为 66.4 和 37.36 个月;p=0.001),而年龄和性别则没有显著影响。关于并发症,与 45Gy 剂量相比,使用 35Gy 可使白内障、青光眼和视网膜脱离的发生率降低 50%以上。视网膜病变、视神经病变和玻璃体积血无明显影响。视力丧失从 45Gy 时的 83.7%显著下降至 35Gy 时的 31.4%(p=0.006),以及放射后眼球切除术:45Gy 时为 23.9%,35Gy 时为 6.45%(p=0.018)。放射后 5 年内记录的视力明显优于 45Gy。
使用 35Gy 可显著降低并发症、视力丧失和挽救性眼球切除术的发生率,同时不影响患者生存率。